Shows
BiotechTV - NewsLondon based Baseimmune shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will use its AI platform to discover and develop new vaccinesCo-founder & CEO Joshua Blight talks about Baseimmune's platform, which was inspired by the work that happened during COVID both in the UK and abroad. The company's current focus is on COVID and malaria.2025-04-2912 min
BiotechTV - NewsLondon based Laverock shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will be doing its work on programmable gene silencingCEO David Venables describes Laverock's platform that repurposed miRNA to reprogram cells in a highly specific way. It's own lead programs will be in oncology and regenerative medicine.2025-04-2912 min
BiotechTV - NewsThe London BioScience Innovation Centre (LBIC) today launched its new Apex Building lab space facility for biotech companies in the heart of the Kings Cross Knowledge QuarterDr. Rich Ferrie gives BiotechTV a preview of the new facilities and describes how it is aimed for growing companies that have already achieved a series A or B. It has started at 37% occupancy on launch day.2025-04-2909 min
BiotechTV - NewsOn its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes being Fc silent will allow Arcus to succeed in TIGIT where others have failed, and a CD73 program that is enrolling very quickly in pancreatic cancer.2025-04-1717 min
BiotechTV - NewsAs federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impactCSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research circles. Plus, his take on what regulatory reforms could help U.S. competitiveness, and areas of research that excite him today.2025-04-1612 min
BiotechTV - NewsSiren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companiesFounder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors that come with it as an asset for her company.2025-04-1610 min
BiotechTV - NewsTheravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system atrophy. A commercial stage company that already receives income from two therapies (YUPELRI and TRELEGY), Theravance Biopharma's future direction and focus will be determined by the outcome of this key trial.2025-04-1516 min
BiotechTV - NewsMarea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering targetCEO Josh Lehrer and CSO Ethan Weiss describe the biology of the target and highlight the topline data, which was first announced at #JPM25. Plus, details on a new program targeting acromegaly.2025-04-1517 min
BiotechTV - NewsAfter switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editorCo-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to lower LDL by over 50% in patients with a genetic form of hypercholesterolemia.2025-04-1419 min
BiotechTV - NewsMount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us whyDr. Schlessinger descrbies how the new center is meant to speed up drug discovery work and enable Mount Sinai researchers to develop molecules that are more dynamic and with a higher success rate. It might also enable them to take drug development further than they traditionally have before.2025-04-1011 min
BiotechTV - NewsJones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they coverThey discusses takeaways from the conference, and comment on Beam, Korro, Wave, Intellia, Prime, Janux, Alto Nuero, Rapport, and YmAbs.2025-04-1014 min
BiotechTV - NewsJones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a yearCFO David Nassif describes the unmet need that still exists today in HAE, and updates us on programs in both the acute and prophylactic settings.2025-04-1007 min
BiotechTV - NewsJones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for JuneHe describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates, and his take on the current environment in biotech.2025-04-1013 min
BiotechTV - NewsJones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington'sHe describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance on when to expect clinical updates on other programs.2025-04-1015 min
BiotechTV - NewsJones Healthcare & Technology Innovation Conference: The CIO of XOMA Royalty describes the inner workings of the royalty business, and also how to help with biotech's negative enterprise problemBrad Sitko describes how XOMA is able to do smaller deals than other larger investors in this space, and he gives examples of investments they have made. Plus how to help with the "zombie biotech" problem in some corners of the sector.2025-04-0915 min
BiotechTV - NewsJones Healthcare & Technology Innovation Conference: Trevi Therapeutics CEO Jennifer Good describes recent positive data in refractory chronic cough and previews upcoming IPF dataShe describes how the mechanism of Haduvio differs from other programs in chronic cough, and covers the recent phase 2a RIVER data.2025-04-0911 min
BiotechTV - NewsJones Healthcare & Technology Innovation Conference: Jones Research analysts Catherine Novack and Debanjana Chatterjee share their take on biotech and comment on companies they coverThey discusses the macro and regulatory factors that have affected the sector so strongly, and comment on Wave, Korro, ProQr, Capricor, Trevi, and Kalvista.2025-04-0910 min
Biotech CEO SisterhoodX4 Pharmaceuticals' CEO Paula Ragan on her career and running a commercial stage company in the rare disease spaceInterviewed by Sisterhood editorial board member Erika Smith, Paula Ragan shares her career path and things she has learned along the way. She describes what it is like managing a company during these volatile times for the sector, and previews a big readout X4 will have next year.2025-04-0816 min
The Studio at Kendall SquareElias Zerhouni and Andy Plump discuss the future of multispecific biologicsInterviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind them. They also discuss the differences between pharma and biotech, keys to being an effective R&D leader, and advice for both young and experienced people in their careers.2025-04-0735 min
BioVenture VoiCes with Chris GarabedianEpisode 16: RA Capital's Josh ResnickJosh Resnick describes his career path, which includes working on the venture side of both private funds and pharma (Merck). He explains the different investment strategies of RA Capital, and talks about how the firm's Raven company building incubator fits in. Plus, his thoughts on venture investing in the current environment.2025-04-071h 12
BiotechTV - NewsAnalyst Thursdays: Stifel's Alex Thompson updates us on the latest news and upcoming catalysts in the I&I spaceHe shares his take on biotech and discusses argenx, Immunovant, AnaptysBio, Apogee, Dianthus, and Viridian.2025-04-0416 min
BiotechTV - NewsVida Ventures named Matt Cohen and Brian Goodman new Managing Directors today. BiotechTV caught up with Brian in Vida's Boston officeHe describes his background in life sciences investing and shares his take on the current state of the sector.2025-04-0210 min
The Studio at Kendall SquareCandel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotechThey discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech innovations faced initial development and market pushback, and how good communication typically played a key role in why some overcame hurdles vs others. Plus, a description of Candel's viral immunotherapy approach.Note: IDEA Pharma and Candel have a business relationship (as discussed).2025-04-0231 min
BiotechTV - NewsMiami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestryFounder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better understand how diseases can have different profiles across diverse populations. Plus, how AI will play a role in this work.2025-03-2714 min
Biotech CEO SisterhoodBiotech CEO Sisterhood: Gallop Oncology CEO Luba Greenwood on the importance of the Sisterhood, the Massachusetts life sciences ecosystem, and Gallop's workInterviewed by Normunity CEO Rachel Humphrey at MassBio's 2025 State of Possible Conference, Luba explains how the Sisterhood arms members with important information, she shares the impression of the Massachusetts ecosystem she has gained as a MassBio board member, and also describes the effort against cancer at Gallop that motivates her each day.2025-03-2716 min
BioVenture VoiCes with Chris GarabedianEpisode 15: Mission BioCapital's Steve TregaySteve Tregay describes his career path, including how early roles at Array BioPharma and Novartis led him to found Forma Therapeutics. He describes the founding and growth of LabCentral, for which he is still the chairman today, and how getting a look at entrepreneurs at such an early stage naturally led to the investment work that he and his partners do at Mission BioCapital.2025-03-241h 01
Biotech CEO SisterhoodAlnylam CEO Yvonne Greenstreet on her career path, the importance of diversity of opinions, and leading Alnlyam into a critical phase of growthInterviewed by Sisterhood editorial board member Sheila Gujrathi, Yvonne Greenstreet describes her upbringing and early career as a physician in the UK, her decision to get an MBA, and the mentors who have impacted her path. She describes joining Alnylam in 2016, and the growth that has happened there since then. Plus, how being CEO has been different, and the values she prioritizes as a leader.2025-03-1730 min
BiotechTV - NewsFrom struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changingJimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle cell disease that is now called CASGEVY. He describes what it was like receiving the treatment, and discusses the need for more awareness and access in the sickle cell community worldwide for this type of treatment.2025-03-1511 min
BiotechTV - NewsBonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its targetFounder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when they were Good Therapeutics, and how the follow-on company Bonum aims to test this approach more broadly. He describes how it works, and discusses the initial programs they have chosen, with a LAG3-IL2 being the most advanced.2025-03-1418 min
BiotechTV - NewsAlta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people - from the Timmerman Report 10th Anniversary Celebration in SeattleHe discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on portfolio companies eGenesis and Vir Biotechnology.2025-03-1406 min
BiotechTV - NewsCongratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!Celebrating with the Seattle (and beyond) biotech community.2025-03-1405 min
BiotechTV - NewsTour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiomeCEO Jame Mcllroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to read out immanently.2025-03-1407 min
BiotechTV - NewsTour of Scotland: Scotland's Chief Scientist (Health) describes how new technologies are being embraced in the NHS, and why Scotland is a good place for global companies to run clinical trialsProfessor Dame Anna Dominiczak describes how new technologies are being rolled out in the community equitably, such as digital dermatology, and invites companies to run clinical trials in Scotland.2025-03-1305 min
BiotechTV - NewsHumanX: Generate Biomedicines' CEO Mike Nally describes how he sees AI going from improvements in optimization to drugging the undruggableFrom the big HumanX AI conference in Las Vegas, he describes the overall path he sees AI taking in its contributions to drug development, and gives an update on Generate's programs regarding TSLP, IL13, ADCs, and more.2025-03-1316 min
BiotechTV - NewsTour of Scotland: St. Andrews based Pneumagen aims to prevent viral respiratory infections with an intra-nasally delivered platform that harnesses glycan targeted Carbohydrate Binding Module domainsCo-Founder & CEO Douglas Thomson describes how the company was founded, and walks us through the science. Plus, a recap of recently presented phase 2 data, and the road ahead.2025-03-1305 min
BiotechTV - NewsTour of Scotland: Dundee based Glen Clova Scientific is using virus like particles to lower levels of cytokines in patients experiencing chronic inflammatory conditionsCEO Steven Powell joins BiotechTV from Scotland's Life Sciences Conference and Awards in Glasgow, and explains Glen Clova's expertise in making next generation VLPs. The first clinical program will be in senile pruritus, targeting IL-31.2025-03-1305 min
BiotechTV - NewsTour of Scotland: Mark Cook, Co-Chair of Life Sciences Scotland describes the importance of life sciences to the area and what the government and industry are doing to support itHe describes the assets that Scotland has to offer the industry such as excellent universities that derive innovation and a diverse population that makes it a great region for clinical trials.2025-03-1307 min
BiotechTV - NewsTour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it. Plus, the growth of the company, investor support, and being based in Glasgow.2025-03-1307 min
BiotechTV - NewsTour of Scotland: Vicki Hazley, Associate Director of The Scottish National Investment Bank, discusses how The Bank invests in life sciencesShe describes The Bank's goal of supporting life sciences in Scotland and making a societal impact, how it aims to co-invest with likeminded investors. Plus, examples of investments such as Elasmogen and PneumoWave.2025-03-1308 min
BiotechTV - NewsProfessor Pieter Cullis and Jay Kulkarni, co-founders of NanoVation Therapeutics, discusses the next generation of lipid nanoparticle deliveryProfessor Cullis, one of the original pioneers of LNPs and co-founder of 11 biotechnology companies, describes the challenge of successfully using lipid nanoparticles to deliver payloads to places outside of the liver. Jay Kulkarni, a former postdoc of his who is co-founder and CSO of the company, describes the 'one-stop-shop' capabilities of NanoVation, which has already led to a partnership with Novo Nordisk and others.2025-03-1218 min
BiotechTV - NewsTour of Scotland: Edinburgh based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumorCEO Ken Macnamara describes the science behind this idea and discusses recently presented preclinical data. He highlights the lead program for glioblastoma and plans for the future, and also explains how he believes a patient sample biobank Trogenix has built is key to the company's success in research.2025-03-1210 min
BiotechTV - NewsTour of Scotland: A leading investor who is focused on life sciences in Scotland shares his thoughts on the innovation happening in the areaAndrew McNeill, Managing Partner of St. Andrews based Eos Advisory, introduces us to the firm and some portfolio companies including Dxcover and Laverock Therapeutics.2025-03-1209 min
BiotechTV - NewsAcuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccineCo-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.2025-03-1217 min
BiotechTV - NewsTour of Scotland: Edinburgh based Cumulus Oncology has built a hub and spoke model of creating multiple spin-out companies - it already has three disclosed assetsFounder & CEO Clare Wareing describes the company's design, with an eye towards being capital efficient and investing over and again for the long-term. She describes the lead investments: a PARG inhibitor, GPR68 small molecules, and a GTPase inhibitor.2025-03-1209 min
BiotechTV - NewsTour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligasesCEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit (PPU). The first goal is to go after hard to treat solid tumors.2025-03-1207 min
BiotechTV - NewsTour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeutics. VYNE has also completed a phase 1a with Tay's oral selective BET inhibitor. Plus, how Tay is also working on a small molecule gene therapy program.2025-03-1208 min
BiotechTV - NewsTour of Scotland: University of Dundee has established a world-class Centre for Protein Degradation, one of the hottest emerging modalities in biotechFounder and Director Alessio Ciulli explains the science behind protein degradation. He then describes the facilities that have been built and the work that takes place at the centre, including founding companies like Amphista Therapeutics. Plus, his take on the field more broadly and targets that researchers are going after.2025-03-1224 min
BiotechTV - NewsTour of Scotland: The Head of Business Development at University of Dundee's Drug Discovery Unit talks about how the university helps biopharma companies translate science into medicinesCharlotte Green describes the work that the unit does in tropical diseases, CNS, women's health, and oncology. She also highlights their pharma partnerships and licenses, and cases where independent biotech companies have spun out of the work.2025-03-1105 min
BiotechTV - NewsTour of Scotland: Sir Michael Ferguson introduces the work in life sciences that has built up at The University of Dundee and the specialized centers that have come from itHe discusses speciality work relating to molecular cell biology / signal transduction, and translational science. Plus, the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU), the Drug Discovery Unit, the soon-to-open Innovation Hub, and more.2025-03-1110 min
BiotechTV - NewsA study published in JMIR today showed that Limbic's GenAI-powered chatbot elevated the standard of care for mental health patients in the UK’s National Health Service (NHS)Limbic CEO Ross Harper describes how patients who interacted with Limbic Care attended 42% more therapy sessions and achieved a 25% higher recovery rate compared to standard treatment.2025-03-1009 min
BioVenture VoiCes with Chris GarabedianEpisode 14: Aditum Bio's Joe JimenezJoe Jimenez describes the career path in consumer products that led him to pharma, his time running Novartis, and the idea to co-found Aditum Bio with his partner Mark Fishman. He explains Aditum's investment philosophy, and why they like focusing on translational medicine opportunities that are just heading into the clinic. Plus, his thoughts on making R&D more efficient. 2025-03-101h 13
BiotechTV - NewsAnalyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiatedHe discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus, comments on Structure Therapeutics, Corbus, Skye Bioscience, Zealand, Viking, Altimmune, Terns, and BioAge Labs.2025-03-0635 min
The Studio at Kendall SquareKorro Bio's Ram Aiyar and Novo Nordisk's Uli Stilz discuss their RNA editing collaboration, the field of genetic medicine, and the future of drug discoveryRam Aiyar, President & CEO of Korro Bio, and Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Kendall Square, share their backgrounds and the scope of their work today. They discuss their RNA editing collaboration and how both the smaller and larger companies bring difference skills to these kinds of partnerships. Plus, their visions of what drug discovery might look like ten years from now.2025-03-0530 min
Biotech CEO SisterhoodBiotech CEO Sisterhood: Vir's CEO Marianne De Backer describes her background and leadership style, and joining Vir as it experienced a road bump, but turning it into an opportunity via a key IO dealInterviewed by Sisterhood editorial board member Grace Colón, Marianne De Backer advocates for the importance of getting experience in a diverse set of roles, she describes joining Vir at a time when it had experienced its first setbacks, and how a deal for a T-cell engager program has been transformational.2025-03-0323 min
BiotechTV - NewsOn Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy scienceMatthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the improvements in vector delivery capabilities, and improving the yield and lowering the cost of future treatments, that is possible with the latest generation of gene therapy.2025-02-2811 min
BiotechTV - NewsCambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHLCEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program targeting BRD9, and how the company thinks about partnerships going forward.2025-02-2607 min
BiotechTV - NewsCambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer themCo-Founder and CEO Sam Windsor describes the rationale for using AI to focus more on tox, not efficacy, and gives and example of a drug the company has already in-licensed from a pharma company. Plus, what today's raise will enable the company to do.2025-02-2607 min
BiotechTV - NewsWith unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipelineCEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese partner, an IL18, ZIP12, and more.2025-02-2614 min
BiotechTV - NewsFrom Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he coversHe shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.2025-02-2523 min
The Studio at Kendall SquareDevan Shah and Namita Bisaria, experts in the field of RNA therapies, discuss the year ahead in RNA - opportunities, challenges, AI, fundraising, and moreDevan Shah, Founder & CEO of RNAV8 Bio, and Namita Bisaria, Head of Research, Strategy, and Operations at AIRNA, discusses approaches to RNA they are excited about this year, companies that have impressed them, and challenges ahead. They touch on uncertainties regarding the regulatory environment, how they think AI might, or might not, affect the field, and more.2025-02-2425 min
BioVenture VoiCes with Chris GarabedianEpisode 13: Civilization Ventures' Shahram Seyedin-NoorShahram describes his upbringing as a refugee from Iran, his early career in law and banking, and how his initial experience in the tech industry has benefitted his eye towards life sciences. He recalls founding Civilization Ventures with an initial $1M fund, and talks about what it has quickly grown into today, Plus, his take on AI and the current state of tech bio.2025-02-241h 12
BiotechTV - NewsAustralia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UKCEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy program, while CSO Sara Prickett explains how the peptide approach aims to teach T-cells to correct allergies while not setting off allergic inflammation that today's therapies do.2025-02-2111 min
BiotechTV - NewsOxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug developmentCEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead program for ovarian cancer.2025-02-2111 min
BiotechTV - NewsWith three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS spaceHerriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA filings and data readouts that Axsome has coming up over the near term. Plus, how he thinks about business development and the big picture.2025-02-2022 min
BiotechTV - NewsStoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndromeHe describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's non-dilutive financing could help Stoke realize its goal to be a platform company.2025-02-1909 min
BiotechTV - NewsThe CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophyBo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations from microdystrophin expression down to muscle integrity are important and pointed in the right direction. Plus, why the company secured a $200M raise before releasing the data publicly.2025-02-1925 min
Biotech CEO SisterhoodSerial entrepreneur Sheila Mikhail on overcoming obstacles and getting the job done, including multiple major acquisitions in her own careerInterviewed by ReCode Therapeutics' CEO Shehnaaz Suliman, she describes the journey of co-founding companies including AskBio, Bamboo Therapeutics, Chatham Therapeutics, and Viralgen VectorCore. Plus, advocacy for better breast cancer screening for all women after her own personal experience of finding a tumor that screening had missed.2025-02-1831 min
Biotech CEO SisterhoodAvidity Biosciences' CEO Sarah Boyce discusses a leader's responsibility to address dysfunction and the importance of corporate cultureInterviewed by Sisterhood editorial board member Sheila Gujrathi, Sarah Boyce describes how to recognize dysfunction and the importance of acting on it directly and with clarity. Plus, maintaining Avidity's culture during a period of explosive growth for the company.2025-02-1723 min
The Studio at Kendall SquareThe co-founder of the Scientific Citizenship Initiative discusses the importance of scientific communication, and trying to place STEM PhDs into the Mass. State House as full-time policy advisorsIn a discussion with gene editing technology expert TJ Cradick, Scientific Citizenship Initiative Co-Founder and Co-Director Daniel Pomeroy describes the history and goal of this non-profit organization, and why having a scientific literate citizenry is so important.2025-02-1732 min
BioVenture VoiCes with Chris GarabedianEpisode 12: Flagship Pioneering's Avak KahvejianA General Partner at Flagship Pioneering, Avak describes his upbringing and studies in the Middle East and Montreal, Canada, working in industry at Helicos, and co-founding companies at Flagship since 2011. He discusses Flagship's unique platform of company building and innovation.2025-02-171h 02
BiotechTV - NewsPaula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their successSponsored Content: She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory expertise, nimbleness, consulting and strategy skills, modeling and biostatistics knowhow, and more.2025-02-1310 min
BiotechTV - NewsWelcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributorRyan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.2025-02-1305 min
BiotechTV - NewsOppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this yearMichael Margolis discusses the macro and policy factors that are in play this year, comments on the China factor, and describes how companies have been trading, and their ability to raise money, off of data.2025-02-1114 min
BiotechTV - NewsJohn Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City TherapeuticsHe gives an optimistic take on the sector, describes why he thinks policy reforms can be positive but should be done strategically and carefully, and why he decided to launch City Therapeutics.2025-02-1118 min
BiotechTV - NewsMizuho Senior Biotech Analyst Salim Syed shares his take on 2025 and key catalysts from companies he coversHe discusses BridgeBio, Cytokinetics, Wave, Vaxcyte, Iovance, Unity, and Enliven.2025-02-1124 min
BioVenture VoiCes with Chris GarabedianEpisode 11: Pillar VC's Tony KulesaA Partner at Pillar VC, Tony describes his start at MIT, founding the MIT BioMakerspace, his work at Petri, being an early supporter of Nucleate, and his philosophy of not being overly influenced by what is in vogue today.2025-01-271h 16
Biotech CEO SisterhoodMary Lynne Hedley shares advice on board makeup, running meetings, and other factors into having an effective board of directorsInterviewed by Sisterhood editorial board member Julia Owens, Dr. Hedley, who was the co-founder of TESARO and today is a member of numerous boards, speaks about the types of discussions board members should be having, best practices for the length of board meetings, and how to ensure that management is doing its job correctly. Plus, advice for current and aspiring CEOs.2025-01-2126 min
BioVenture VoiCes with Chris GarabedianEpisode 10: Curie.Bio's Alexis BorisyThe Co-Founder and Operating Chairman of Curie.Bio, and serial entrepreneur, shares experiences from his early life, CombinatoRx, Foundation Medicine, Third Rock, EQRx and more.2025-01-131h 20
Biotech CEO SisterhoodA leadership series discussion on building an effective board, best practices for running meetings, hiring talent, and decision makingSisterhood editorial board members Daphne Zohar (Seaport Therapeutics) and Luba Greenwood (Gallop Oncology) share their experiences about what types of leaders do and don't make good board members, how to efficiently manage meetings and discussions, and general leadership skills of running a company.2025-01-0628 min
BioVenture VoiCes with Chris GarabedianEpisode 9: Alloy Therapeutics & 82VS's Errik AndersonHe describes his career path and learnings from the tech industry, co-founding Adimab, the work that Alloy and 82VS do to support and invest in scientist-entrepreneurs, and why he believes smaller organizations are best suited for discovery work and other early stage innovation. 2024-12-301h 13
Biotech CEO SisterhoodHeather Turner and Sheila Gujrathi discuss managing your board of directors effectivelyInterviewed by Sisterhood editorial board member Sheila Gujrathi, former Carmot Therapeutics CEO and newly named CEO of LB Therapeutics Heather Turner talks about communications skills and other best practices for CEOs to have an effective working relationship with their board of directors.2024-12-1926 min
BioVenture VoiCes with Chris GarabedianEpisode 8: Canaan Partners' Julie GrantA general partner the firm, she describes her career path, including time spent at Goldman Sachs and Genentech, before landing at Canaan over a decade ago. She discusses the firm's investment approach to healthcare, and boldly moving into new categories of medicine even in cases where an organization doesn't have existing commercial infrastructure.2024-12-181h 07
Biotech CEO SisterhoodMelinta Therapeutics CEO Christine Miller on expanding the company into the acute care business, improving employee satisfaction, and her leadership principlesInterviewed by Sisterhood editorial board member Grace Colón, Christine Miller describes taking the job at Melinta after a business reorganization and in the middle of the pandemic, and where and how she has led the business since. Plus, the importance of investing in the antimicrobial space.2024-12-1227 min
Biotech CEO SisterhoodDeborah Dunsire on trends in drug development, investments, regulation, and her advice on key skills for growing into a position of leadershipInterviewed by Sisterhood editorial board member Erika Smith, Deborah Dunsire describes her career path, how medicine is making progress in areas such as neuroscience, the cyclical nature of biotech and what it means for investment risk, and more.2024-12-0519 min
BioVenture VoiCes with Chris GarabedianEpisode 7: MPM BioImpact's Ansbert GadickeMPM's founder and managing partner discusses the firm's 30+ years of investing in life sciences, including the philosophy of placing entrepreneur partners at companies from the start, and teaming up with research institutions and investment collaborators. Plus, the keys making it through a down cycle like the industry has been in over recent years.2024-12-021h 10
The Studio at Kendall SquareA patient advocacy group founded by two parents has partnered with a biotech company on a gene therapy for limb-girdle muscular dystrophy Type 2C/R5 - it was just cleared to start a clinical trialDion Foundation Co-Founder and President Courtney Dion discusses with Atamyo Therapeutics CEO Stéphane Degove the many ways that patient advocate groups can support the work that biotech companies do.2024-11-1920 min
BioVenture VoiCes with Chris GarabedianEpisode 6: Omega Funds' Otello StampacchiaHe describes his career path, including time in the lab and doing quant work at Goldman Sachs. Plus, what he has learned about VC investing and biotech over time, and how Omega Funds is able to successfully invest in various stages and rounds of companies.2024-11-181h 15
The Studio at Kendall SquareJanssen's Elena Diez and Odyssey Therapeutics' Gary Glick share advice on success factors for pharma - biotech partnerships, and moreThey discuss Odyssey's work, the investments it has made regarding in silico and AI/ML tools, the unique value of the Boston biotech ecosystem, and keys to successful collaborations.2024-11-1320 min
BioVenture VoiCes with Chris GarabedianEpisode 5: KdT Ventures' Founder and Managing Partner Cain McClaryHe describes this path to venture investing from his start in science at the NIH to becoming a pathologist, and eventually raising a modest first fund and building off of its success. Plus, his investment philosophy and investing in science - including outside of therapeutics.2024-11-041h 04
The Studio at Kendall SquareKojin Therapeutics Chairman & CEO Harvey Berger shares an update on the company's progress and talks about the funding environment for earlier stage companies in biotechBiotech industry veteran Harvery Berger talks about his company's job at hand to translate the science of ferroptosis into therapies. Plus, a warning about the currently very difficult funding environment for preclinical and other early stage companies in the sector.2024-10-2515 min
The Studio at Kendall SquareTranscriptional regulation in disease: opportunities, challenges, and the futureCigall Kadoch, associate professor and HHMI Investigator, Dana-Farber Cancer Institute and Harvard Medical School, and scientific founder of Foghorn Therapeutics (NASDAQ: FHTX), interviews Rick Young, professor of biology at MIT and member of the Whitehead Institute about the latest research and knowledge of how transcriptional regulation can be harnessed and targeted in drug development.2024-10-2419 min
The Studio at Kendall SquareA father and patient advocate discuss Canavan disease and a daughter's experience on a gene therapy clinical trialLauren Celano, a board member of the National Tay-Sachs & Allied Diseases Association, interviews Lee Greenwood about his family's experience with Canavan disease and how patient organizations and innovative research have impacted their journey from the beginning.2024-10-2339 min
BioVenture VoiCes with Chris GarabedianEpisode 4: Enavate Sciences’ Sara NayeemSara Nayeem describes her career path and how different firms she has worked for have had different approaches to investing. She introduces us to Enavate Sciences, and shares her thoughts on investing in various areas such as rare diseases and digital health.2024-10-211h 03
The Studio at Kendall SquareGene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPRFor this high-tech emerging field within biotech, it is important to get safety right. They discuss the keys to understanding the possible range of edits, choosing the right assay, assessing and reporting the possible outcomes, and more.2024-10-1726 min
The Studio at Kendall SquareGeorge Church on founder led companies, synthetic biology technologies, the future, and moreDan Mandell, Co-Founder and CEO of GRO Biosciences, interviews professor Church about the Genomically Recoded Organisms (GRO) platform that Dan spun out of his lab, asks him what technologies he is working on that excite him today, and gets his take on the sustainability of life on Earth and the opportunity to read or write the human brain.2024-10-0736 min
BioVenture VoiCes with Chris GarabedianEpisode 3: Time BioVentures' D.A. WallachD.A. Wallach describes how he went from music to healthcare/biotech investing, and the similarities he sees between the two industries. Plus, the firm's investment philosophy and how he partnered with Tim Wright to create the firm.2024-10-071h 04
The Studio at Kendall SquareGene therapy experts TJ Cradick and Kate Excoffon discuss using AAV gene therapy for cystic fibrosisDr. Excoffon describes her academic experience that led her to the field and Spirovant Sciences, discusses interesting data from last month’s North American Cystic Fibrosis Conference, and then highlights Spirovant’s program and why using a small molecule modulator like doxorubicin might be the key to success.2024-10-0324 min
The Studio at Kendall SquareImmuno-Oncology experts Zhen Su and Kristen Hege discuss the latest in the field and preview #SITC24Dr. Su and Dr. Hege talk about solving the cell therapy solid tumor challenge, the latest in bi-specifics, her recent hike of the Pacific Crest Trail for charity, and a preview of the upcoming SITC annual meeting in November.2024-10-0119 min
BioVenture VoiCes with Chris GarabedianEpisode 2: Westlake BioPartners’ Beth SeidenbergBeth Seidenberg tells the story of how her career went from physician, to product development in industry, to investor. She describes the qualities she looks for in an entrepreneur, and discusses the Los Angeles core of Westlake BioPartners.2024-09-2357 min
BioVenture VoiCes with Chris GarabedianEpisode 1: Venrock's Bryan RobertsBryan Roberts discusses Venrock's history, moving from NYC to the Bay Area, his investment philosophy, portfolio construction and concentration, the types of entrepreneurs he looks for, what qualities make for a good early stage investor, thoughts on AI, Tech Bio, and more.2024-09-091h 06